PMID- 36343054
OWN - NLM
STAT- MEDLINE
DCOM- 20221109
LR  - 20221116
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 101
IP  - 44
DP  - 2022 Nov 4
TI  - Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic 
      therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis.
PG  - e31479
LID - 10.1097/MD.0000000000031479 [doi]
LID - e31479
AB  - BACKGROUND: This study aimed to compare the efficacy and safety of immune 
      checkpoint inhibitors (ICIs) combined with antiangiogenic agents in patients with 
      unresectable hepatocellular carcinoma (HCC). METHODS: We conducted a systematic 
      literature search of articles published between the establishment of the database 
      and February 2022. Data were extracted and analyzed using STATA 14.0. RESULTS: 
      Six randomized controlled trials (RCTs) (980 patients for combination therapy and 
      565 patients for monotherapy) and 5 single-arm studies (246 patients for ICIs 
      combination therapy) were enrolled. The objective response rate (ORR) and disease 
      control rate (DCR) were 26% and 70%, respectively, after ICIs combination 
      therapy. Compared with monotherapy in RCTs, ICIs combination therapy resulted in 
      higher progression-free survival (PFS) and overall survival (OS), but also 
      increased the incidence of adverse events (AEs). Increased incidences of fatigue, 
      hypertension, hyperbilirubinemia, proteinuria, and nausea were more common after 
      ICIs combination therapy. CONCLUSION: The analysis results reveal that 
      ICI-combined anti-angiogenesis therapy has higher efficacy than either ICIs or 
      anti-angiogenesis options for unresectable HCC, but it is necessary to manage the 
      AEs.
CI  - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Xian, Feng
AU  - Xian F
AUID- ORCID: 0000-0002-1310-3506
AD  - School of Medicine, University of Electronic Science and Technology of China, 
      Chengdu, China.
AD  - Department of Oncology, Nanchong Central Hospital, Nanchong, China.
FAU - Wu, Cailiang
AU  - Wu C
AD  - Department of Pathology, Nanchong Central Hospital, Nanchong, China.
FAU - Zhang, Guojun
AU  - Zhang G
AD  - Department of Oncology, Nanchong Central Hospital, Nanchong, China.
FAU - Xu, Guohui
AU  - Xu G
AD  - School of Medicine, University of Electronic Science and Technology of China, 
      Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - Immune Checkpoint Inhibitors/adverse effects
MH  - Immunotherapy/methods
MH  - Combined Modality Therapy
MH  - *Liver Neoplasms/drug therapy
PMC - PMC9646576
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2022/11/08 06:00
MHDA- 2022/11/10 06:00
PMCR- 2022/11/04
CRDT- 2022/11/07 14:04
PHST- 2022/11/07 14:04 [entrez]
PHST- 2022/11/08 06:00 [pubmed]
PHST- 2022/11/10 06:00 [medline]
PHST- 2022/11/04 00:00 [pmc-release]
AID - 00005792-202211040-00037 [pii]
AID - 10.1097/MD.0000000000031479 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2022 Nov 4;101(44):e31479. doi: 
      10.1097/MD.0000000000031479.